Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new UNAIDS report indicates that ambitious targets to prevent and treat HIV in babies and children are not being met.
A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.
For pregnant women with HIV, dolutegravir-based regimens are apparently safest.
The study randomized women starting HIV treatment during their third trimester to dolutegravir- or efavirenz-based antiretroviral regimens.
Updated recommendation includes testing for pregnant women during each pregnancy.
Sexually transmitted infections reach all-time highs, notably among young people.
Pregnant women with HIV often don’t receive treatment per guidelines, according to a study of more than 1,800 HIV-positive pregnant women.
Interim guidance from HIVMA and AIDSinfo covers lab visits, opioid treatment programs, pregnant women and more.
This may not lower PrEP’s efficacy, but very strict adherence to the daily Truvada regimen is key for pregnant women.
Viral load and CD4 percentage at the time of treatment initiation help predict how soon infants will become undetectable.
“You must be closed up because you HIV people like making babies, and it just annoys us.”
Despite unanswered questions about PrEP’s safety and efficacy for pregnant women, they shouldn’t be denied Truvada for HIV prevention.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
I’ve got a proper measuring tool—and a good reason to use it.
Researchers infected 1-month-old primates with HIV-like virus and 30 hours later injected them with a pair of antibodies.
A study of more than 1,800 HIV-positive pregnant women looked at whether they were prescribed guideline-recommended antiretrovirals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.